RecruitingPulmonary HypertensionInterstitial Lung Disease
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Eligible age
18–80 yrs
Accepts
All genders
Locations
17 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Sponsor: Liquidia Technologies, Inc.
Where it's recruiting
Arizona
Phoenix
California
Fresno · La Jolla · Los Angeles · Sacremento …
Colorado
Denver
Connecticut
Hartford
Florida
Orlando · Tampa
Indiana
Indianapolis
Kentucky
Louisville
Massachusetts
Boston
Michigan
Ann Arbor
Minnesota
Minneapolis
New York
New York · Rochester
North Carolina
Chapel Hill
Source: ClinicalTrials.gov · NCT06129240 · last updated 2026-06-26